Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
$1.66
-2.6%
$2.83
$1.52
▼
$5.89
$30.81M0.36234,568 shs36,187 shs
Biofrontera Inc. stock logo
BFRI
Biofrontera
$0.57
-5.0%
$0.95
$0.54
▼
$1.66
$8.91M0.88201,130 shs113,372 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.17
-1.7%
$1.35
$0.85
▼
$1.93
$29.86M1.82486,334 shs160,039 shs
United-Guardian, Inc. stock logo
UG
United-Guardian
$7.15
-6.4%
$7.21
$5.58
▼
$9.95
$35.10M0.9923,150 shs15,357 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
-8.85%-26.41%-30.04%-61.80%-52.78%
Biofrontera Inc. stock logo
BFRI
Biofrontera
+1.10%-36.02%-25.56%-59.47%-26.87%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
+2.59%-13.77%-8.46%-9.16%-13.77%
United-Guardian, Inc. stock logo
UG
United-Guardian
+1.06%-11.06%+12.19%+7.15%+26.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
$1.66
-2.6%
$2.83
$1.52
▼
$5.89
$30.81M0.36234,568 shs36,187 shs
Biofrontera Inc. stock logo
BFRI
Biofrontera
$0.57
-5.0%
$0.95
$0.54
▼
$1.66
$8.91M0.88201,130 shs113,372 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.17
-1.7%
$1.35
$0.85
▼
$1.93
$29.86M1.82486,334 shs160,039 shs
United-Guardian, Inc. stock logo
UG
United-Guardian
$7.15
-6.4%
$7.21
$5.58
▼
$9.95
$35.10M0.9923,150 shs15,357 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
-8.85%-26.41%-30.04%-61.80%-52.78%
Biofrontera Inc. stock logo
BFRI
Biofrontera
+1.10%-36.02%-25.56%-59.47%-26.87%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
+2.59%-13.77%-8.46%-9.16%-13.77%
United-Guardian, Inc. stock logo
UG
United-Guardian
+1.06%-11.06%+12.19%+7.15%+26.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.57
Moderate Buy$10.00504.23% Upside
Biofrontera Inc. stock logo
BFRI
Biofrontera
1.50
ReduceN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.00
Buy$6.00412.82% Upside
United-Guardian, Inc. stock logo
UG
United-Guardian
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest BFRI, UG, ATHE, and NNVC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/4/2026
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
10/19/2026
United-Guardian, Inc. stock logo
UG
United-Guardian
Reiterated RatingHold (C)
10/13/2026
Biofrontera Inc. stock logo
BFRI
Biofrontera
Reiterated RatingSell (D-)
10/12/2026
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
9/15/2026
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
Initiated CoverageBuy$10.00
9/15/2026
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
Initiated CoverageBuy$10.00
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/A$1.60 per shareN/A
Biofrontera Inc. stock logo
BFRI
Biofrontera
$41.71M0.20N/AN/A($0.02) per share-28.50
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
United-Guardian, Inc. stock logo
UG
United-Guardian
$10.55M3.11$0.45 per share15.85$2.44 per share2.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
-$15.88MN/AN/AN/AN/AN/AN/AN/AN/A
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$10.54M-$0.25N/AN/AN/A-12.72%-131.54%-29.61%N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.53N/AN/AN/AN/A-87.90%-78.69%N/A
United-Guardian, Inc. stock logo
UG
United-Guardian
$2.11M$0.6811.23N/AN/A25.16%27.84%23.68%N/A

Latest BFRI, UG, ATHE, and NNVC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$0.11-$0.42-$0.31-$0.42$8.50 million$9.07 million
11/9/2026Q3 2026
United-Guardian, Inc. stock logo
UG
United-Guardian
N/A$0.20N/A$0.20N/A$3.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/AN/A
Biofrontera Inc. stock logo
BFRI
Biofrontera
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
United-Guardian, Inc. stock logo
UG
United-Guardian
$0.608.39%-5.11%88.24%1 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/A
14.52
14.52
Biofrontera Inc. stock logo
BFRI
Biofrontera
0.78
0.78
1.08
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47
United-Guardian, Inc. stock logo
UG
United-Guardian
N/A
6.50
5.92

Institutional Ownership

CompanyInstitutional Ownership
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.14%
Biofrontera Inc. stock logo
BFRI
Biofrontera
10.08%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%
United-Guardian, Inc. stock logo
UG
United-Guardian
23.16%

Insider Ownership

CompanyInsider Ownership
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
38.80%
Biofrontera Inc. stock logo
BFRI
Biofrontera
8.10%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
2.80%
United-Guardian, Inc. stock logo
UG
United-Guardian
29.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
1118.13 million11.09 millionNot Optionable
Biofrontera Inc. stock logo
BFRI
Biofrontera
9414.85 million13.65 millionNo Data
NanoViricides, Inc. stock logo
NNVC
NanoViricides
725.53 million14.92 millionOptionable
United-Guardian, Inc. stock logo
UG
United-Guardian
254.59 millionN/ANot Optionable

Recent News About These Companies

United-Guardian Reports Higher Third Quarter Earnings
How United-guardian Inc. (UG) Affects Rotational Strategy Timing
Upside Gold Announces September Investor Outreach Schedule
United-Guardian: Q2 Earnings Snapshot
United-Guardian Reports Second Quarter Results
United-Guardian Declares Cash Dividend
United-Guardian Reports First Quarter Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:ATHE

$1.66 -0.05 (-2.65%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 +0.03 (+1.81%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Biofrontera stock logo

Biofrontera NASDAQ:BFRI

$0.57 -0.03 (-4.97%)
Closing price 04:00 PM Eastern
Extended Trading
$0.62 +0.05 (+8.95%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.17 -0.02 (-1.68%)
Closing price 04:00 PM Eastern
Extended Trading
$1.19 +0.02 (+1.71%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

United-Guardian stock logo

United-Guardian NASDAQ:UG

$7.15 -0.49 (-6.41%)
Closing price 04:00 PM Eastern
Extended Trading
$7.67 +0.52 (+7.27%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.